Entos Pharmaceuticals announced today two candidates for a DNA vaccine they call Covigenix using their proprietary Fusogenix drug delivery platform. The DNA vaccines are pan-coronavirus, including COVID-19, a disease caused by a particular strain of the coronavirus.
See our daily updated COVID-19 vaccine tracker where we track every manufacturer of the COVID-19 vaccine.
In the company's recently concluded pre-clinical studies, the company observed positive results of SARS-CoV-2 neutralizing antibodies in addition to meeting antibody-dependent enhancement safety standards.
According to a representative from Entos,
“Based on the preclinical in vivo safety and efficacy data, we believe our Fusogenix DNA vaccine candidates have the potential to be safe and highly potent vaccines that will provide protection against COVID-19 as well as future coronavirus threats,” said John Lewis, CEO of Entos Pharmaceuticals. “These results reflect the potential of our Fusogenix drug delivery platform which has allowed us to quickly advance lead vaccine candidates to animal challenge studies. We look forward to continue working closely with our collaborators to initiate Phase I/II human clinical trials this summer.”
Entos received a $4.2M grant from the Canadian Institutes of Health Research (CIHR), Research Nova Scotia (RNS). The company plans to develop Covigenix in successive trials, both animal and human, with the Institute for Ageing (IA) where the Phases I and II human clinical trials will be evaluated in late July with an aim of developing 1 million vaccines in just one year.
The currently held record for the fastest vaccine to be developed is from 1963 when Maurice Hilleman swabbed his own daughter's throat and developed the Measles, Mumps, and Rubella (MMR) vaccine totaling four years of development.